Several gene expression and immune monitoring studies conducted on clinical samples have reported that increased CD2 expression is correlated with improved survival rates in patients with melanoma, breast cancer, AML and diffuse large B-cell lymphoma (DLBCL)149–152. This evidence concerns the gene CD2 and diffuse large B-cell lymphoma.